Toro Company vice president Amy Dahl to depart at end of September
Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics Inc (NASDAQ:AXSM), sold a total of 45,783 shares of common stock on September 16, 2025. The sales, executed under a pre-approved 10b5-1 plan, resulted in proceeds of approximately $5.2 million. The transaction comes as the $5.8 billion market cap company maintains impressive gross profit margins of 91.5%, though InvestingPro data shows the stock has declined 6% over the past week.
Jacobson sold 5,783 shares at a price of $116.19, totaling $671,926. Additionally, he sold 40,000 shares at a weighted average price of $114.23, for a total of $4,569,200; the prices for these shares ranged from $112.93 to $116.87. According to InvestingPro analysis, the stock currently trades below its Fair Value, with analyst targets ranging from $144 to $200 per share.
On the same day, Jacobson also exercised options to acquire 40,000 shares of Axsome Therapeutics common stock. These transactions involved the exercise of 25,000 options with an exercise price of $4.95 per share and 15,000 options with an exercise price of $4.85 per share, totaling $196,500. These options were set to expire. For comprehensive insider trading analysis and additional financial metrics, access the detailed Pro Research Report available on InvestingPro.
In other recent news, Axsome Therapeutics has been the focus of several analyst updates and strategic developments. Piper Sandler maintained its Overweight rating on the company with a price target of $148, gaining insights into Axsome’s strategies for expanding its products, including Auvelity for major depressive disorder and Symbravo for acute migraine. Cantor Fitzgerald also reiterated its Overweight rating with a $153 price target, although it slightly reduced its revenue projections for Sunosi, a medication for narcolepsy and obstructive sleep apnea. Wells Fargo initiated coverage with an Overweight rating and a $163 price target as Axsome plans to submit a supplemental New Drug Application for AXS-05, targeting Alzheimer’s Disease Agitation, by the third quarter of 2025.
Additionally, H.C. Wainwright reaffirmed its Buy rating and set a $180 price target despite a generic challenge to Symbravo, a combination of meloxicam and rizatriptan benzoate. This challenge arose after Axsome received a Paragraph IV Certification Notice from Apotex, which seeks approval to manufacture a generic version of Symbravo. Mizuho also maintained its Outperform rating and a $200 price target amid this generic challenge, as revealed in Axsome’s 8-K filing. These developments reflect ongoing confidence from analysts in Axsome’s strategic direction and product pipeline, despite challenges in the competitive landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.